This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Alexion Pharma Skips Out on Paying U.S. Taxes, Wall Street Says Hurrah!

Alexion Pharmaceuticals (ALXN - Get Report) is up 21% to $162.11 Thursday, not because of another "beat and raise" quarter, but because the company is moving operations to Ireland so that it can avoid higher U.S. corporate taxes. 

In 2014, Alexion's corporate tax rate will be 11-12%, much lower than the mid-20% tax rate expected by investors and analysts. And Alexion's tax rate will remain low forever now that "technical operations" are domiciled in Ireland. Alexion said Thursday that its tax rate will rise to 13-14% in 2015 and 16-18% in 2016 and beyond. -- still well below what the company would pay in the U.S.

Alexion is just the latest drug company to pursue the strategy of " inversion" -- the relocation of corporate headquarters or business operations from the U.S. to more tax-friendly countries like Ireland. Many companies invert by acquiring Irish-based businesses. Alexion is doing something different. It acquired a factory in Ireland where its drugs are packaged into vials. By establishing this factory in Ireland, Alexion was then able to transfer "technical operations" and key patents on its main drug Soliris from the U.S. and Switzerland to its Irish affiliate. 

And with that move, Alexion avoids paying higher U.S. corporate taxes. Wall Street cheers. 

On a call with investors this morning, Alexion CEO Leonard Bell insisted the company's decision to "realign its corporate structure" was done to better serve patients. Bell was reading from a script, no doubt crafted by his lawyers and spin doctors because the company knows running away to Ireland to shaft Uncle Sam may make good business sense, but looks lousy from a public relations perspective.

On the call, Bell didn't say if he'd be leaving his tony home in Connecticut, where Alexion is officially headquartered, to live in a garret above his new Irish vialing plant.

Somehow, I doubt it. Alexion's taxes are the only thing really moving.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.


Chart of I:DJI
DOW 15,914.74 -99.64 -0.62%
S&P 500 1,851.86 -0.35 -0.02%
NASDAQ 4,283.5920 +14.8290 0.35%

Adam's Tweets

Select the service that is right for you!

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Growth Seeker

Chris Versace, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Daily Swing Trade

Master swing trader Alan Farley uses his sophisticated software screens to review thousands of stocks each day for you, to find just the handful that meet his demanding criteria.

Product Features:
  • Daily commentary and coaching on swing trading
  • Technical charts and analysis
Top Rated Stocks Top Rated Funds Top Rated ETFs